Guide to Tildrakizumab Dosing & Administration

About

The Ilumya (tildrakizumab) Dosing Calculator is a clinical support tool designed for healthcare professionals to quickly generate an administration schedule for patients with moderate-to-severe plaque psoriasis. By providing a starting date, it maps out the induction and maintenance doses over a specified period, simplifying treatment planning and patient counseling.

Outputs

After entering the initial dose date, the calculator generates a clear, table-based dosing schedule that includes:

• Dose Number: A sequential count of each administration.
• Treatment Phase: Identifies whether the dose is part of the initial ‘Induction’ phase or the long-term ‘Maintenance’ phase.
• Week: The corresponding week of treatment (e.g., Week 0, Week 4, Week 16).
• Calculated Date: The specific calendar date for each scheduled subcutaneous injection.
• Day of the Week: The day of the week for the scheduled administration to aid in patient planning.

How to Use

To generate a dosing schedule, follow these simple steps:

1. Enter First Dose Date: Using the date picker, select the day the patient receives their first 100 mg dose of Ilumya. This is considered Week 0.
2. Select Duration: Choose the desired length of the schedule from the dropdown menu (e.g., 1, 2, 3, or 5 years).
3. Calculate: The tool automatically calculates and displays the full administration schedule based on your inputs. The schedule can be recalculated at any time by changing the start date or duration.

Dosing Overview

Ilumya (tildrakizumab) is administered as a 100 mg subcutaneous injection according to the following FDA-approved schedule for adults with moderate-to-severe plaque psoriasis:

• Induction Phase: The first two doses are given 4 weeks apart.
  • Initial dose (100 mg) at Week 0
  • Second dose (100 mg) at Week 4
• Maintenance Phase: Subsequent doses are administered every 12 weeks.
  • Third dose (100 mg) at Week 16
  • All following doses (100 mg) are given every 12 weeks (Q12W) thereafter.

Switching

When switching a patient from another systemic therapy or biologic to Ilumya, the decision on timing should be based on clinical judgment. Considerations include the mechanism of action and half-life of the previous medication to minimize the risk of disease flare or adverse events. There is no required washout period, but the first dose of Ilumya is typically administered when the next dose of the prior therapy would have been due.

Missed Dose

According to the prescribing information, if a patient misses a dose of Ilumya, the missed dose should be administered as soon as possible. After that, dosing should be resumed at the regularly scheduled time. The calculator does not adjust for missed doses; it generates an ideal schedule from the start date.

Safety Alerts

Frequently Asked Questions

What is the standard maintenance dose schedule for Ilumya?

After the initial doses at Week 0 and Week 4, the maintenance schedule for Ilumya is a 100 mg subcutaneous injection once every 12 weeks (Q12W).

Does this calculator adjust for a missed dose?

No. The calculator generates a perfect, uninterrupted dosing schedule from the selected start date. For guidance on a missed dose, please refer to the prescribing information and the “Missed Dose” section above.

Can I change the date format for the output?

Yes. The tool includes a toggle to switch the displayed dates between MM/DD/YYYY (US format) and DD/MM/YYYY (International format) to suit your preference.

What is the recommended dose of Ilumya?

The recommended dose is 100 mg for all patients, regardless of body weight.

How is Ilumya administered?

Ilumya is administered via subcutaneous (SC) injection.

What should I do after the calculated schedule ends?

The patient should continue with the maintenance dosing of 100 mg every 12 weeks for as long as prescribed by their healthcare provider.

Is this tool a substitute for professional medical advice?

No. This tool is for educational and informational purposes only and is not a substitute for clinical judgment or the official prescribing information. Always verify dosing schedules and clinical decisions with the full prescribing information.

Why are the first two doses (Week 0 and Week 4) scheduled closer together?

This is the induction or “loading” phase. The initial, more frequent dosing helps the patient reach therapeutic drug levels more quickly to achieve a rapid clinical response.

References

1. ILUMYA® (tildrakizumab-asmn) Prescribing Information. U.S. Food and Drug Administration.
2. Ilumya® Healthcare Professional Website. Sun Pharmaceutical Industries, Inc.
3. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
4. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276-288.